First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Novartis
Washington University School of Medicine
Institut Bergonié
SafeHeal Inc
University of Iowa
University of Iowa
Washington University School of Medicine
Peter MacCallum Cancer Centre, Australia
National Cancer Institute (NCI)
Mayo Clinic
Seoul National University Hospital
National Cancer Institute (NCI)
University of Pittsburgh
Gilead Sciences
Stanford University
M.D. Anderson Cancer Center
University of Rochester
Eastern Cooperative Oncology Group
Eisai Inc.
Vilnius University
The Christie NHS Foundation Trust
Universitätsklinikum Hamburg-Eppendorf
Washington University School of Medicine
Swiss Cancer Institute
Washington University School of Medicine
Oxford University Hospitals NHS Trust
Targovax ASA
PharmaEngine
Fox Chase Cancer Center
Region Västmanland
National Institutes of Health Clinical Center (CC)
University of Maryland, Baltimore
NSABP Foundation Inc
Hospital Universitario La Fe
OHSU Knight Cancer Institute
Gilead Sciences
West China Hospital
Fox Chase Cancer Center
Brown University
UNICANCER
West China Hospital
Instituto Nacional de Cancer, Brazil
American College of Radiology Imaging Network
Norwegian University of Science and Technology
UNC Lineberger Comprehensive Cancer Center
Novadaq Technologies ULC, now a part of Stryker
University Hospital, Geneva
Instituto do Cancer do Estado de São Paulo
Merck Sharp & Dohme LLC